ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Genmab A S (PK)

Genmab A S (PK) (GNMSF)

216.14
5.17
(2.45%)
Cerrado 18 Febrero 3:00PM

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
216.14
Postura de Compra
195.02
Postura de Venta
235.12
Volume Operado de la Acción
512
214.708 Rango del Día 216.59
186.61 Rango de 52 semanas 323.018
Capitalización de Mercado [m]
Precio Anterior
210.97
Precio de Apertura
215.686
Última hora de negociación
Volumen financiero
US$ 110,606
Precio Promedio Ponderado
216.0272
Volumen promedio (3 m)
4,613
Acciones en circulación
65,691,573
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
3.11
Beneficio por acción (BPA)
66.25
turnover
16.47B
Beneficio neto
4.35B

Acerca de Genmab A S (PK)

Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.

Sector
Biological Pds,ex Diagnstics
Industria
Biogenetic (human)
Sitio web
Sede
Copenhagen, Dnk
Fundado
2000
Genmab A S (PK) is listed in the Biological Pds,ex Diagnstics sector of the OTCMarkets with ticker GNMSF. The last closing price for Genmab A S (PK) was US$210.97. Over the last year, Genmab A S (PK) shares have traded in a share price range of US$ 186.61 to US$ 323.018.

Genmab A S (PK) currently has 65,691,573 shares in issue. The market capitalisation of Genmab A S (PK) is US$13.86 billion. Genmab A S (PK) has a price to earnings ratio (PE ratio) of 3.11.

GNMSF Últimas noticias

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
125.67213.4783795703190.468216.59186.7671202.54397887CS
42.2441.04910797771213.896217.4186.617050194.57453545CS
1212.946.36811023622203.2227.35186.614613201.37814755CS
26-49.06-18.4992458522265.2282.06186.615775215.95277595CS
52-70.16-24.5057631855286.3323.018186.613626228.22888291CS
156-120.36-35.7682020802336.5470.5186.611793266.7862133CS
260-27.06-11.1266447368243.2500.92159.451689287.75347836CS

GNMSF - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Genmab A S (PK)?
El precio actual de las acciones de Genmab A S (PK) es US$ 216.14
¿Cuántas acciones de Genmab A S (PK) están en circulación?
Genmab A S (PK) tiene 65,691,573 acciones en circulación
¿Cuál es la capitalización de mercado de Genmab A S (PK)?
La capitalización de mercado de Genmab A S (PK) es USD 13.86B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Genmab A S (PK)?
Genmab A S (PK) ha negociado en un rango de US$ 186.61 a US$ 323.018 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Genmab A S (PK)?
El ratio precio/beneficio de Genmab A S (PK) es 3.11
¿Cuál es el ratio de efectivo a ventas de Genmab A S (PK)?
El ratio de efectivo a ventas de Genmab A S (PK) es 0.82
¿Cuál es la moneda de reporte de Genmab A S (PK)?
Genmab A S (PK) presenta sus resultados financieros en DKK
¿Cuál es el último ingresos anual de Genmab A S (PK)?
El último ingresos anual de Genmab A S (PK) es DKK 16.47B
¿Cuál es el último beneficio anual de Genmab A S (PK)?
El último beneficio anual de Genmab A S (PK) es DKK 4.35B
¿Cuál es la dirección registrada de Genmab A S (PK)?
La dirección registrada de Genmab A S (PK) es KALVEBOD BRYGGE 43, COPENHAGEN, 1260
¿Cuál es la dirección del sitio web de Genmab A S (PK)?
La dirección del sitio web de Genmab A S (PK) es www.genmab.com
¿En qué sector industrial opera Genmab A S (PK)?
Genmab A S (PK) opera en el sector BIOGENETIC (HUMAN)

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
ELYSElys BMG Group Inc (CE)
US$ 0.0004
(39,900.00%)
5.14k
YRIVYangtze River Port and Logistics Ltd (CE)
US$ 0.0001
(9,900.00%)
2.39k
SIRCSolar Integrated Roofing Corporation (PK)
US$ 0.0001
(9,900.00%)
15.01M
NXTPNextPlay Technologies Inc (CE)
US$ 0.0001
(9,900.00%)
2.21k
MFLTYMissfresh Ltd (CE)
US$ 0.0001
(9,900.00%)
103
AUSAFAustralis Capital Inc (CE)
US$ 0.000001
(-99.99%)
20.5k
AGCZAndes Gold Corp (CE)
US$ 0.000001
(-99.75%)
40.14k
FVTIFortune Valley Treasures Inc (CE)
US$ 0.0015
(-99.40%)
589
EGRNFChina Evergrande Group (CE)
US$ 0.0001
(-99.01%)
5k
AHFDActive Health Foods Inc (CE)
US$ 0.000001
(-99.00%)
500k
TKMOTekumo Inc (PK)
US$ 0.0002
(-20.00%)
261.44M
GTLLGlobal Technologies Ltd (PK)
US$ 0.0003
(0.00%)
229.69M
RDARRaadr Inc (PK)
US$ 0.0008
(14.29%)
138.89M
AITXArtificial Intelligence Technology Solutions Inc (PK)
US$ 0.00305
(15.09%)
131.8M
HMBLHUMBL Inc (PK)
US$ 0.0005
(0.00%)
126.35M

GNMSF Discussion

Ver más
XenaLives XenaLives 5 años hace

Products in development
Genmab is developing a pipeline of antibody therapeutics with eighteen products in clinical development, including two marketed products, and approximately 20 in-house and partnered pre-clinical programs. Our pipeline currently includes naked antibodies, Antibody Drug Conjugates (ADCs), bispecific antibodies created from our DuoBody® technology platform, and antibodies created with our HexaBody® technology.


http://www.genmab.com/product-pipeline/products-in-development
👍️0
XenaLives XenaLives 5 años hace

Product pipeline
Genmab has two partnered products on the market, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and is developing a clinical pipeline of antibody therapeutics for the treatment of cancer.


http://www.genmab.com/product-pipeline

👍️0
XenaLives XenaLives 5 años hace

About Genmab A/S
Genmab A/S operates as a biotechnology company. The Company specializes in development of antibody therapeutics for the treatment of cancer. Genmab serves customers worldwide.


ADDRESS
Kalvebod Brygge 43 Copenhagen V, 1560 Denmark
PHONE
45-7020-2728
WEBSITE
www.genmab.com






https://www.bloomberg.com/quote/GMXAY:US
👍️0
XenaLives XenaLives 5 años hace
GMXAY largest holding in Blackrock fund:

iShares Genomics Immunology and Healthcare ETF


https://www.blackrock.com/us/individual/products/308878/
👍️0
PennyStock Alert PennyStock Alert 5 años hace
Genmab Announces Phase II Study of Daratumumab in Non-Hodgkin's Lymphomas

[GlobeNewswire] - Company Announcement

read full: http://finance.yahoo.com/news/genmab-announces-phase-ii-study-063632870.html
👍️0
TenKay TenKay 7 años hace
GMXAY Forward Split 5 for 1 effective May 1, 2018

http://otce.finra.org/DailyList
👍️0
trendmkr trendmkr 9 años hace
Here are Two Biotech Stocks to Watch in January - article mentions Genmab

http://marketexclusive.com/here-are-two-biotech-stocks-to-watch-in-january/1228/
👍️0
stocktrademan stocktrademan 10 años hace
$GMXAY DD Notes ~ http://www.ddnotesmaker.com/GMXAY

bullish

$GMXAY recent news/filings

## source: finance.yahoo.com

Thu, 04 Dec 2014 06:36:32 GMT ~ Genmab Announces Phase II Study of Daratumumab in Non-Hodgkin's Lymphomas

[GlobeNewswire] - Company Announcement

read full: http://finance.yahoo.com/news/genmab-announces-phase-ii-study-063632870.html
*********************************************************

Mon, 24 Nov 2014 13:53:34 GMT ~ Genmab Announces Phase II Study of Daratumumab in Smoldering Multiple Myeloma

[GlobeNewswire] - Company Announcement

read full: http://finance.yahoo.com/news/genmab-announces-phase-ii-study-135334071.html
*********************************************************

Mon, 10 Nov 2014 08:17:15 GMT ~ Genmab Announces New Phase III Combination Study of Daratumumab in Frontline Multiple Myeloma

[GlobeNewswire] - Company Announcement

read full: http://finance.yahoo.com/news/genmab-announces-phase-iii-combination-081715458.html
*********************************************************

Thu, 06 Nov 2014 14:40:06 GMT ~ Genmab Announces Daratumumab and Ofatumumab Data to Be Presented at American Society of Hematology Annual Meeting (ASH)

[GlobeNewswire] - Media Release

read full: http://finance.yahoo.com/news/genmab-announces-daratumumab-ofatumumab-data-144006800.html
*********************************************************

Thu, 06 Nov 2014 14:10:48 GMT ~ Genmab Announces Additional Data from Phase III Study of Ofatumumab as Maintenance Therapy for Relapsed CLL

[GlobeNewswire] - COPENHAGEN, Denmark -- Genmab A/S (OMX: GEN) announced today additional data from the interim analysis of the ofatumumab (Arzerra(tm)) Phase III study, PROLONG (OMB112517). The study evaluated ofatumumab ...

read full: http://finance.yahoo.com/news/genmab-announces-additional-data-phase-141048186.html
*********************************************************


$GMXAY charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$GMXAY company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/GMXAY/company-info
Ticker: $GMXAY
OTC Market Place: OTC Pink Current
CIK code: 0001434265
Company name: Genmab A/S
Company website: http://www.genmab.com
Incorporated In: Denmark

Business Description: Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.


$GMXAY share structure

## source: otcmarkets.com

Market Value: $2,578,167,309 a/o Dec 03, 2014
Shares Outstanding: 51,052,818 a/o Jul 30, 2013
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$GMXAY extra dd links

Company name: Genmab A/S
Company website: http://www.genmab.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=GMXAY+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=GMXAY+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=GMXAY+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/news - http://finance.yahoo.com/q/h?s=GMXAY+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/GMXAY/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=GMXAY+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/GMXAY
DTCC (dtcc.com): http://search2.dtcc.com/?q=Genmab+A%2FS&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Genmab+A%2FS
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Genmab+A%2FS&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.genmab.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.genmab.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.genmab.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/GMXAY
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001434265&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=GMXAY&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=GMXAY
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=GMXAY+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=GMXAY+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=GMXAY
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=GMXAY
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=GMXAY+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/GMXAY/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=GMXAY+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/GMXAY.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=GMXAY
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/GMXAY
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/GMXAY
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/GMXAY:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=GMXAY
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=GMXAY



$GMXAY DD Notes ~ http://www.ddnotesmaker.com/GMXAY
👍️0
akademikeren akademikeren 11 años hace
Genmab has taken a beating along with a lot of american Biotech. It is poised for a lot of news starting the 19th of april with a PDUFA date on their submission on 1st line CLL drug Arzerra. For those of you unfamiliar with this Company I will be posting news regularly and tell you something about the history.
👍️0

Su Consulta Reciente

Delayed Upgrade Clock